GRAL
GRAIL Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 110 | +3 | 19.61M | $1.34B | +13 | −10 |
| Q1 2026 | 110 | -6 | 18.56M | $959.35M | +4 | −11 |
| Q4 2025 | 117 | +2 | 17.78M | $1.52B | +3 | — |
| Q3 2025 | 18 | +1 | 10.99M | $649.07M | +2 | −2 |
| Q2 2025 | 15 | -1 | 10.50M | $537.63M | +1 | −2 |
| Q1 2025 | 13 | +1 | 6.08M | $155.14M | +2 | −1 |
| Q4 2024 | 12 | +2 | 5.32M | $94.90M | +3 | −1 |
| Q3 2024 | 9 | -6 | 3.74M | $51.49M | — | −6 |
| Q2 2024 | 15 | — | 4.39M | $67.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 1.87M | — | $28.67M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 798.02K | — | $12.27M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 421.77K | — | $6.48M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 351.83K | — | $5.41M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 303.85K | — | $4.67M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 246.27K | — | $3.79M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 80.95K | — | $1.24M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Soros Fund Management ✦ | 75.00K | — | $1.15M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 68.91K | — | $1.06M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Capital World Investors ✦ | 67.14K | — | $1.03M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 60.80K | — | $934,557 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | GAMCO Investors ✦ | 20.00K | — | $307,400 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 19.14K | — | $295,000 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 14.95K | — | $226,566 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 15 | Baillie Gifford ✦ | 606 | — | $9,314 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 9.40K shares, $485 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 23.62K sh · $3.46M
Officer · 7.87K sh · $1.15M
Officer · 1.80K sh · $169,048
Officer · 521 sh · $49,495
Officer, Director · 2.12K sh · $196,170
Officer, Director · 1.45K sh · $136,103
Officer, Director · 6.20K sh · $597,871
Officer, Director · 1.40K sh · $136,978
Officer, Director · 421 sh · $42,037
Officer, Director · 2.10K sh · $211,429
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology